Essential Topics for Internal Medicine Resident Lectures
Hypertension Management: Evidence-Based Updates
Target blood pressure <130/80 mmHg for most patients with diabetes, with intensive targets (<120 mmHg systolic) providing additional cardiovascular benefit in high-risk populations. 1, 2
Blood Pressure Targets and Evidence
The 2017 ACC/AHA guidelines redefined hypertension as ≥130/80 mmHg, based primarily on the SPRINT trial demonstrating 25% reduction in cardiovascular events and 27% reduction in mortality with intensive systolic targets (<120 mmHg). 3, 2
For patients with diabetes specifically, the ADVANCE trial showed that achieving mean SBP/DBP of 136/73 mmHg reduced major cardiovascular events by 9%, cardiovascular death by 18%, and all-cause mortality by 14% compared to 141.6/75.2 mmHg. 3
The STEP trial in elderly patients (60-80 years, including those with diabetes) demonstrated that targeting SBP <130 mmHg versus <150 mmHg reduced composite cardiovascular outcomes by 26% and cardiovascular death by 28%. 3
The 2024 ESC guidelines introduced a simplified three-tier BP categorization: non-elevated (<120/70 mmHg), elevated (120-139/70-89 mmHg), and hypertension (≥140/90 mmHg), with treatment targets of 120-129 mmHg systolic for most adults. 2
Measurement and Diagnosis Essentials
Accurate BP measurement is foundational—use proper technique with appropriate cuff size, patient seated with back supported, feet flat, arm at heart level, after 5 minutes of rest. 1, 2
Utilize ambulatory BP monitoring or home BP monitoring to identify white coat hypertension (elevated office BP but normal out-of-office readings) and masked hypertension (normal office BP but elevated out-of-office readings). 4
Screen for secondary causes in patients with resistant hypertension: chronic kidney disease, renovascular disease, primary aldosteronism, pheochromocytoma, Cushing's syndrome, coarctation of the aorta, and obstructive sleep apnea. 4
Pharmacologic Management Algorithm
Initiate ACE inhibitors or ARBs as first-line therapy in patients with diabetes and hypertension, particularly those with albuminuria or chronic kidney disease. 4, 5, 6
For patients with compelling indications (post-MI, heart failure with reduced ejection fraction), use β-blockers for at least 3 years post-MI in those with preserved left ventricular function. 5
Thiazide-like diuretics (chlorthalidone, indapamide) are preferred over hydrochlorothiazide for superior cardiovascular outcomes. 1
Combination therapy is typically required—the ADVANCE trial used fixed-dose perindopril/indapamide combination with significant mortality benefit. 3
Critical Pitfalls to Avoid
Clinical inertia—failure to titrate medications when BP remains above goal is a major barrier to control. Use decision support systems (electronic or paper-based algorithms) to prompt treatment intensification. 7
Do not discontinue antihypertensive therapy abruptly in pregnant patients—the CHAP trial demonstrated that treating to <140/90 mmHg in pregnancy with chronic hypertension improved outcomes without fetal harm. 3
More lenient targets (systolic 130-139 mmHg) are appropriate for very elderly patients (≥85 years), those with frailty, or symptomatic orthostatic hypotension. 2
Type 2 Diabetes: Cardiovascular and Renal Protection
SGLT2 inhibitors and GLP-1 receptor agonists should be prioritized in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, independent of glycemic control needs. 5
SGLT2 Inhibitors: Cardiovascular and Renal Benefits
The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death, with particular benefit in patients with established cardiovascular disease (99% of trial participants had CVD). 5
The combined CANVAS/CANVAS-R trials showed canagliflozin reduced the composite outcome of cardiovascular death, MI, or stroke (HR 0.86,95% CI 0.75-0.97) in patients with mean age 63 years, 66% with prior CVD. 5
SGLT2 inhibitors provide additive renoprotection in diabetic patients with proteinuria >300 mg/g, regardless of glycemic control status—add to ACE inhibitor/ARB therapy for synergistic benefit. 6
Monitor for increased risk of lower-limb amputation with canagliflozin (HR 1.97,95% CI 1.41-2.75 in CANVAS program). 5
GLP-1 Receptor Agonists: Cardiovascular Outcomes
Consider liraglutide, semaglutide, or dulaglutide in diabetic patients with CVD or very high/high cardiovascular risk to reduce cardiovascular events and mortality. 6
These agents provide cardiovascular benefit beyond glycemic control and promote weight loss, addressing multiple metabolic risk factors simultaneously. 5
Comprehensive Risk Factor Management
Target LDL-C <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline in type 2 diabetes patients at very high cardiovascular risk using statin therapy as first-line. 6
Use ACE inhibitors or ARBs in all diabetic patients with hypertension or diabetic kidney disease—these agents reduce cardiovascular outcomes and slow CKD progression. 5
Finerenone (a non-steroidal mineralocorticoid receptor antagonist) should be considered in type 2 diabetes patients with CKD to reduce cardiovascular outcomes and CKD progression risk. 5
Lifestyle Intervention Framework
Prescribe at least 150 minutes per week of moderate-intensity aerobic plus resistance activity—emphasize that any amount of physical activity provides benefit. 8
Ensure adequate sleep (7-9 hours nightly) to improve insulin sensitivity and reduce inflammation. 8
Restrict dietary sodium to <2.0 g/day, which is synergistic with ACE inhibitor/ARB therapy and essential for BP control. 6
Limit alcohol consumption to ≤1 drink per day for women and ≤2 drinks per day for men. 8
Monitoring Parameters
Regularly assess BMI, waist circumference, blood pressure, lipid profiles, hemoglobin A1c, and kidney function (eGFR, urine albumin-to-creatinine ratio). 8
Screen for sleep disorders (particularly obstructive sleep apnea), which worsen insulin resistance, hypertension, hyperglycemia, and dyslipidemia. 8
Use non-invasive tests like FIB-4 to assess for liver involvement (NAFLD/NASH), with appropriate hepatology referral for intermediate to high-risk fibrosis. 8
Chronic Kidney Disease: Proteinuria and Hypertension Management
Initiate ACE inhibitor or ARB as first-line therapy and uptitrate to maximum tolerated dose (not just to BP control) in all patients with proteinuria ≥1 g/day, targeting proteinuria reduction to <1 g/day. 6
Diagnostic Workup and Risk Stratification
Quantify proteinuria using spot urine protein-to-creatinine ratio or 24-hour urine collection to establish baseline severity. 6
Measure baseline serum creatinine and eGFR to assess renal function, and evaluate for secondary causes (diabetes, autoimmune disease, multiple myeloma). 6
Assess cardiovascular risk factors including lipid panel and hemoglobin A1c if diabetic—CKD patients are at very high cardiovascular risk. 6
Pharmacologic Treatment Algorithm
Target systolic blood pressure <120 mmHg in most patients with proteinuria, using ACE inhibitor or ARB as foundation regardless of baseline BP. 6
Accept up to 30% increase in serum creatinine after starting ACE inhibitor/ARB—this is an expected hemodynamic effect indicating appropriate glomerular pressure reduction. 6
Check labs every 2-4 weeks initially: serum creatinine, eGFR, potassium, and urine protein-to-creatinine ratio. 6
Add-On Therapy for Inadequate Response
Add thiazide-like diuretic (or loop diuretic if eGFR <30 mL/min/1.73m²) for volume overload or resistant hypertension. 6
Add low-dose spironolactone or eplerenone for resistant proteinuria despite maximized ACE inhibitor/ARB and diuretic—provides additional antiproteinuric effect. 6
Add SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) in diabetic patients with proteinuria >300 mg/g for additive renoprotection and cardiovascular benefit. 6
Treatment Targets and Monitoring
Target proteinuria reduction of ≥25% by 3 months, ≥50% by 6 months, aiming for absolute proteinuria <1 g/day or at least 30-50% reduction from baseline. 6
Dietary sodium restriction to <2.0 g/day is mandatory and synergistic with ACE inhibitor/ARB therapy—non-negotiable for optimal proteinuria reduction. 6
CKD and Venous Thromboembolism Risk
All severities of kidney disease increase VTE risk: mild-to-moderate CKD confers 1.3-2-fold increased risk, end-stage renal disease 2.3-fold increased risk, and nephrotic syndrome up to 23-fold increased risk within first 3 months of diagnosis. 9, 10, 11
The association persists even with microalbuminuria and remains elevated for >5 years, particularly in nephrotic syndrome and glomerulonephritis. 11
Mechanisms include hemostatic derangements with procoagulant activity, platelet dysfunction, endothelial dysfunction, and inflammation. 9, 10
Venous Thromboembolism: Treatment in Special Populations
Rivaroxaban is FDA-approved for treatment of DVT and PE, with dosing adjustments required for renal impairment—use with caution in CKD and avoid in severe renal impairment (CrCl <30 mL/min for DVT/PE treatment). 12
Rivaroxaban Dosing for VTE Treatment
Standard DVT/PE treatment: 15 mg twice daily for 21 days, then 20 mg once daily for continued treatment and reduction of recurrent VTE risk. 12
Renal dosing considerations: rivaroxaban requires dose adjustment in renal impairment due to significant renal elimination. 12
Premature discontinuation increases thrombotic event risk—counsel patients on importance of adherence and do not stop without alternative anticoagulation plan. 12
Critical Safety Considerations
Spinal/epidural hematoma risk with neuraxial anesthesia or spinal puncture—delay rivaroxaban dosing appropriately and monitor for neurologic impairment. 12
Bleeding risk is increased—avoid in patients with active pathological bleeding and use caution with concomitant antiplatelet agents or NSAIDs. 12
Avoid concomitant use with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, phenytoin). 12
VTE Risk in CKD Patients
Proteinuria itself is an independent VTE risk factor—the association is present even for microalbuminuria and increases with severity of proteinuria. 9, 10
Risk is highest within first 3 months after CKD diagnosis but remains elevated long-term, particularly in nephrotic syndrome (adjusted OR 2.89,95% CI 2.26-3.69). 11
Consider VTE prophylaxis in hospitalized CKD patients, especially those with nephrotic-range proteinuria, acute kidney injury, or recent kidney transplant. 9, 11
Emerging Infectious Diseases: Preparedness Framework
Core Competencies for Residents
Maintain updated knowledge of local and global infectious disease surveillance through CDC, WHO, and state health department resources. 4
Understand principles of infection control, isolation precautions, and personal protective equipment use for emerging pathogens with pandemic potential. 4
Recognize clinical presentations of re-emerging infections (tuberculosis, measles) and novel pathogens, with low threshold for infectious disease consultation. 4
Practical Approach to Suspected Emerging Infections
Obtain detailed travel history (including layovers), animal exposures, sick contacts, and occupational exposures in all patients with fever or systemic illness. 4
Implement appropriate isolation precautions immediately based on clinical syndrome (respiratory, contact, airborne) before definitive diagnosis. 4
Coordinate with infection prevention, infectious disease specialists, and public health authorities for suspected reportable diseases. 4
Patient Education and Adherence Strategies
Adopt an attitude of empathetic reinforcement—provide positive feedback for BP and behavioral improvements, and schedule more frequent appointments for patients not achieving goals. 7
Effective Communication Techniques
Assess patient's understanding and acceptance of their diagnosis, discussing concerns and clarifying misunderstandings at each visit. 7
Tell patients their BP reading and provide written documentation—come to agreement on goal BP and ask patients to rate (1-10) their likelihood of adhering to treatment. 7
Provide specific written information about lifestyle modifications including diet, physical activity, and medication regimens using standard brochures when available. 7
Overcoming Barriers to Adherence
Anticipate adherence problems in young men and consider non-adherence as a cause of resistant hypertension or sudden loss of BP control. 7
Encourage patients to bring all medications (prescription, over-the-counter, complementary) to each visit for medication reconciliation. 7, 8
Ask specifically about pain medication use (NSAIDs can elevate BP and interfere with antihypertensive efficacy). 7
Recognize and appropriately manage depression and psychiatric illness, which significantly impair treatment adherence. 7
Multidisciplinary Care Coordination
Refer patients with diabetes to certified diabetes care and education specialists (CDCES) when available to improve disease management and reduce complications. 8
Use shared decision-making when initiating pharmacological treatments, considering patient priorities to improve adherence and outcomes. 8
Organize care delivery systems with decision support prompts to advance therapy when goals are not achieved, reducing clinical inertia. 7